Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo

Int Immunopharmacol
September 2020
https://pubmed.ncbi.nlm.nih.gov/32585612/

Dr. Armin Schwarzbach, Infections in Cancer and Autoimmune Disorders. Presented by Markus Berger.

Dana Flavin, MD - Reversing Cancer with Biochemistry (2018 Conference) (LDN, low dose naltrexone)

Dr Dana Flavin shares her presentation on Reversing Cancer at the LDN 2018 Conference.

Akbar Khan, MD - Cancer Case Studies (2016 Conference) (LDN, low dose naltrexone)

In this presentation Dr Khan talks about many case studies involving Transitional cell carcinoma (TCC), colon cancer and Adenoid cystic carcinoma (ACC), explaining how Low Dose Naltrexone (LDN) can improve the lives of cancer patients.

Akbar Khan, MD - Cancer Therapy (2016 Conference) (LDN, low dose naltrexone)

Download Dr. Khan's Cancer Presentation

Nasha Winters, ND - Navigating the Narrative (2017 Conference) (LDN, low dose naltrexone)

Dr Nasha Winters speaks from experience when she talks about Cancer and how to be proactive in preventing and/or combating it. In her youth she was diagnosed with a terminal Cancer, but discovered the life changes that would turn it around. 

Paul Battle PA-C - Effects of LDN on Cancer (2017 Conference) (LDN, low dose naltrexone)

Martin Dayton, DO - LDN Case Studies (2016 Conference) (LDN, low dose naltrexone)

Dr Martin Dayton shares three case studies of patients suffering from follicular B-cell non Hodgkin's Lymphoma who were treated with nothing more than Low Dose Naltrexone (LDN). 

Laurie Marzell, ND - LDN Case Studies (2017 Conference) (LDN, low dose naltrexone)

Akbar Khan, MD - LDN for Cancer prevention (2018 Conference) (LDN, low dose naltrexone)